EUVIMEDEUVIMED entdecken
Open Access

Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis

Chandrayee Ghosh, Tejinder Pal Khaket, Viswanath Gunda, Zhongyue Yang, Jiangnan Hu, Eden Demissie Alamaw, Lisa Zhang, Ya-Qin Zhang, Min Shen, Yasmine Tabdili, Myriem Boufraqech, Rodas Kassu und 1 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Chandrayee Ghosh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Stanford University, Stanford, CA, USA. Electronic address: cghosh@stanford.edu. Hauptthemen laut MEDLINE: Apoptosis, Thiazoles, Auranofin, Oxidative Stress. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, US Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid cancer (ATC) has one of the highest mortality rates of all human malignancies and has no cure. We used combination drug matrix screening of highly active compounds and identified that combination of nitazoxanide and auranofin was one of those with the highest synergistic anticancer activity. We investigated its synergistic anticancer activity and mechanism of action in preclinical ATC models. We performed in vitro, ex vivo, and in vivo ATC models to evaluate the synergistic anticancer activity and the mechanism of action of this combination. Combination nitazoxanide and auranofin treatment synergistically inhibited cellular proliferation, colony formation, and cellular migration compared to control and single agents. Combination treatment also significantly reduced ATC cell line and patient-derived ATC spheroid size. Nitazoxanide alone and in combination with auranofin caused ER stress and apoptosis. Auranofin alone and in combination with nitazoxanide induced activation of the ROS generating pathway. This led to enhanced increase in ROS and MDA levels with combination treatment associated with upregulation of HMOX-1 and cell death that was reversed by N-acetyl cysteine (NAC). The combination significantly inhibited tumor growth in vivo in 8505C ATC cells, and C643 ATC cells, without significant treatment-related toxicity. Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in vitro, ex vivo, and in vivo in ATC, which is due to enhanced oxidative stress and induction of apoptosis compared to single-drug treatment. Both drugs are FDA approved; their combination is a potential candidate for evaluation in a clinical trial for ATC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisThiazolesAuranofinOxidative StressThyroid Carcinoma, AnaplasticAntineoplastic Combined Chemotherapy ProtocolsThyroid NeoplasmsHumansNitro CompoundsDrug SynergismAnimalsCell Line, TumorCell ProliferationXenograft Model Antitumor AssaysReactive Oxygen SpeciesMice, NudeMiceCell MovementFemale

Stichwörter der Autor:innen

Anaplastic thyroid cancerAuranofinCell deathCombination therapyNitazoxanideSynergism

Substanzen

nitazoxanideNitro CompoundsThiazolesAuranofinReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Surgery, Stanford University, Stanford, CA, USA. Electronic address: cghosh@stanford.edu.
  • Department of Surgery, Stanford University, Stanford, CA, USA.
  • Department of Comparative Medicine, Veterinary Service Center, Stanford University, Stanford, CA, USA.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
  • National Center for Advancing Translational Sciences, National Institute of Health, Bethesda, MD, USA.
  • University of Arizona, College of Medicine, Tucson, AZ, USA.

Förderung

  • Intramural NIH HHS
  • National Institutes of Health
  • US Department of Defense
  • Stanford University
  • National Cancer Institute

Zitieren

APA

Ghosh, C., Khaket, T. P., Gunda, V., Yang, Z., Hu, J., Alamaw, E. D., Zhang, L., Zhang, Y. Q., Shen, M., Tabdili, Y., Boufraqech, M., Kassu, R., & Kebebew, E. (2025). Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217990

Vancouver

Ghosh C, Khaket TP, Gunda V, Yang Z, Hu J, Alamaw ED, et al. Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217990

BibTeX
@article{Ghosh2025,
  author = {Ghosh, Chandrayee and Khaket, Tejinder Pal and Gunda, Viswanath and Yang, Zhongyue and Hu, Jiangnan and Alamaw, Eden Demissie and Zhang, Lisa and Zhang, Ya-Qin and Shen, Min and Tabdili, Yasmine and Boufraqech, Myriem and Kassu, Rodas and Kebebew, Electron},
  title = {Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217990}
}
Kostenlos starten →